Lord Botham

HL8744 • Cerliponase Alfa

To ask His Majesty's Government what assessment they have made of how the decision to limit Brineura access from January 2026 aligns with the Rare Diseases Framework; and what action they will take to ensure continued progress in rare disease treatment equity.

HL8688 • Batten Disease: Cerliponase Alfa

To ask His Majesty's Government what assessment they have made of the impact of ineligibility to receive cerliponase alfa for treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) on children born after January 2026; and what steps they are taking to ensure equitable access to treatment for all future patients who are diagnosed with CLN2.

HL8689 • Batten Disease: Cerliponase Alfa

To ask His Majesty's Government why provision of cerliponase alfa to children with neuronal ceroid lipofuscinosis type 2 will be restricted from January 2026, and what engagement they have had with NHS England, the National Institute for Health and Care Excellence, and BioMarin regarding future access and funding arrangements.

HL8690 • Batten Disease: Cerliponase Alfa

To ask His Majesty's Government whether they plan to revisit the Managed Access Agreement for Brineura for treating neuronal ceroid lipofuscinosis type 2 to ensure that children born after January 2026 are not excluded from the treatment.

HL8691 • Batten Disease: Medical Treatments

To ask His Majesty's Government what estimate they have made of the number of children born annually in the UK with neuronal ceroid lipofuscinosis type 2 after January 2026, and what alternative treatments will be available should they be ineligible for treatment with Brineura.

HL8692 • Batten Disease: Cerliponase Alfa

To ask His Majesty's Government what equality impact assessment they have carried out in regard to the decision to end access to Brineura for patients diagnosed with neuronal ceroid lipofuscinosis type 2 after January 2026.

HL8693 • Batten Disease: Cerliponase Alfa

To ask His Majesty's Government what discussions they have had with BioMarin and the National Institute for Health and Care Excellence regarding the long-term sustainability of access to Brineura for children with neuronal ceroid lipofuscinosis type 2 beyond the expiration of the current managed access agreement.

HL2387 • Private Education: VAT

To ask His Majesty's Government what consideration they have given to differentiating between independent schools with (1) fewer than 200 pupils, and (2) more than 200 pupils, with regard to the imposition of VAT.

HL2342 • Private Education: Business Rates

To ask His Majesty's Government what consideration they have given to making independent schools eligible for transitional relief for business rates.

HL2343 • Private Education: VAT

To ask His Majesty's Government what consideration they have given to phasing in the introduction of VAT for independent schools.